Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-Label Extension Study of Zilucoplan in Generalized Myasthenia Gravis
2019-001565-33Phase 3Active
- Sponsor
- Ra Pharmaceuticals
- Start
- Oct 2019
- Modality
- Cyclic Peptides → Modified Peptides → Peptides
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of zilucoplan in myasthenia gravis (MG), sponsored by Ra Pharmaceuticals. Primary endpoint: Incidence of TEAEs. Started Oct 2019; status: active.
02
Drugs
zilucoplan
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on 2019-001565-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001565-33.